Velasco-de Andrés María, Muñoz-Sánchez Guillermo, Carrillo-Serradell Laura, Gutiérrez-Hernández María Del Mar, Català Cristina, Isamat Marcos, Lozano Francisco
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Servei d'Immunologia, Centre de Diagnòstic Biomèdic, Hospital Clínic de Barcelona, Barcelona, Spain.
Eur J Immunol. 2023 Mar;53(3):e2250184. doi: 10.1002/eji.202250184. Epub 2023 Feb 6.
Adoptive cell transfer (ACT) therapies have gained renewed interest in the field of immunotherapy following the advent of chimeric antigen receptor (CAR) technology. This immunological breakthrough requires immune cell engineering with an artificial surface protein receptor for antigen-specific recognition coupled to an intracellular protein domain for cell activating functions. CAR-based ACT has successfully solved some hematological malignancies, and it is expected that other tumors may soon benefit from this approach. However, the potential of CAR technology is such that other immune-mediated disorders are beginning to profit from it. This review will focus on CAR-based ACT therapeutic areas other than oncology such as infection, allergy, autoimmunity, transplantation, and fibrotic repair. Herein, we discuss the results and limitations of preclinical and clinical studies in that regard.
随着嵌合抗原受体（CAR）技术的出现，过继性细胞转移（ACT）疗法在免疫治疗领域重新引起了人们的关注。这一免疫学突破需要对免疫细胞进行工程改造，使其具有用于抗原特异性识别的人工表面蛋白受体，并与用于细胞激活功能的细胞内蛋白结构域相结合。基于CAR的ACT已成功解决了一些血液系统恶性肿瘤，预计其他肿瘤可能很快也会从这种方法中受益。然而，CAR技术的潜力使得其他免疫介导的疾病也开始从中获益。本综述将聚焦于除肿瘤学之外基于CAR的ACT治疗领域，如感染、过敏、自身免疫、移植和纤维化修复。在此，我们讨论这方面临床前和临床研究的结果及局限性。
